TransCon-TLR-7/8-agonist

Ascendis Pharma's YORVIPATH is set to launch in the U.S. by mid-January 2025, with significant revenue growth reported ex-U.S. in Q3 2024.

Ascendis Pharma has reported its second quarter 2024 financial results, highlighting progress in its clinical trials for TransCon CNP and oncology programs, alongside a financial update and outlook based on current plans.

Ascendis Pharma A/S provided an update on its Vision 3x3 strategic roadmap and key milestones for 2022 at the 40th Annual J.P. Morgan Healthcare Conference. The company highlighted its progress in 2021, including the U.S. launch of SKYTROFA®, and outlined its plans for clinical data readouts and regulatory submissions across its endocrinology rare disease and oncology portfolios in 2022.